Lanreotide Autogel/Depot (LAN) in Lung Neuroendocrine Tumours (NETs): The Randomized, Double-Blind, Placebo (PBO)-Controlled, International Phase 3 SPINET Study

#1790

Introduction: Treatment options for advanced lung NETs are limited. The phase 3 CLARINET study demonstrated antitumour efficacy of somatostatin analogue (SSA) LAN 120mg vs PBO for metastatic gastroenteropancreatic grade 1/2 (Ki-67<10%) NETs, but prospective data on SSAs in advanced lung NETs are lacking.

Aim(s): This study evaluates safety and antitumour efficacy of LAN 120mg in pts with advanced lung NETs.

Materials and methods: SPINET is a large double-blind, PBO-controlled phase 3 study (NCT02683941; EudraCT: 2015-004992-62). Main inclusion criteria are adults with well-differentiated typical/atypical, metastatic and/or unresectable lung NETs, positive SSTR imaging, ≤1 chemotherapy course, ECOG PS0–1. 216 pts from 80 sites across the USA, Canada and Europe will be randomized 2:1 to either LAN 120mg/28 days or PBO, both with best supportive care, until PD/death or unacceptable toxicity. Pts experiencing PD on PBO may opt to receive LAN 120mg in an open-label extension. All pts experiencing PD will be followed to document survival, QoL and subsequent treatment. Recruitment began in July 2016.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Reidy-Lagunes D, Kulke M, Wolin E, Singh S, Ferone D,

Keywords: Lung NETs, lanreotide,